|
|
Gene Expression Markets in EuropePublished by: Frost & Sullivan Published: Oct. 26, 2006 - 80 Pages Table of Contents
1. Industry Snapshot 1. Executive Summary 2. Exchange Rates and Glossary of Terms 1. Glossary and Exchange Rates 1. Glossary of Terms 2. Exchange Rates 3. Industry Challenges 1. Research Scope and Methodology 1. Research Scope and Methodology 2. Industry Challenges 1. Industry Challenges 4. Market Engineering Research of the Gene Expression Market in Europe 1. Forecasts for Gene Expression Market in Europe 1. Introduction and Market Overview 2. Market Segmentation 3. Market Engineering Measurements 4. Market Drivers a. Demand for Accelerated Drug Discovery b. Increased Throughput Demand on Laboratories c. Gene Expression Technologies are Robust, Efficient and Potent d. Strategic Alliance and Scientific Collaborations Nurture a Growing Trend e. Disease Pathologies Result in Growing use of DNA Microarrays f. Increased End-user Base Expands Market 5. Market Restraints a. Expensive Reagents Restrict Market Growth b. Increased Competitiveness Reduces Prices c. Data Comparison across Platforms d. Inadequate End-user Knowledge of New Technology e. Lack of Research Support in Technology Transfer f. Inadequate Cash Resources for Research 6. Total European Revenue Forecasts 7. Technology Trends 8. Geographical Trends 9. Pricing Trends 10. End Users Trends 11. Competitive Structure 5. DNA Microarrays for the Gene Expression Market in Europe 1. Introduction 1. Market Overview 2. Market Engineering Measurements 1. Market Engineering Measurements 3. DNA Microarrays Revenue Forecast Analysis 1. Revenue Forecast Analysis 4. Competitive Landscape 1. Competitive Structure 6. Real-Time PCR for the Gene Expression Market in Europe 1. Introduction 1. Market Overview 2. Market Engineering Measurements 1. Market Engineering Measurements 3. Real-Time PCR Revenue Forecast Analysis 1. Revenue Forecast Analysis 4. Competitive Landscape 1. Competitive Structure 7. RNAi for the Gene Expression Market in Europe 1. Introduction 1. Market Overview 2. Market Engineering Measurements 1. Market Engineering Measurements 3. RNAi Revenue Forecast Analysis 1. Revenue Forecast Analysis 4. Competitive Landscape 1. Competitive Structure 8. Market Engineering Strategic Recommendations 1. Market Engineering Strategic Recommendations 1. Strategic Recommendations 9. Decision Support Databases 1. Decision Support Databases 1. Decision Support Databases 10. Database of Key Industry Participants 1. Key Industry Participants 1. List of Key Industry Participants List of Figures Chapter 2 Chapter 3 Chapter 4 Chapter 5 Chapter 6 Chapter 7 Chapter 9 AbstractThis research service examines the Gene Expression Markets in Europe in terms of the challenges faced by market participants, drivers and restraints in the industry, the competitive structure in the major markets, the revenue forecasts and growth rates, strategic recommendations and market opportunities.Research Overview This Frost & Sullivan research service titled Gene Expression Markets in Europe provides an overview of gene expression solutions in drug discovery. This study includes a complete analysis of key market drivers, restraints, and trends in the market. Finally, it provides strategic solutions to the vendors to gain advantage in the growing market. In this research, Frost & Sullivan's expert analysts thoroughly examine the following markets: DNA microarrays, Real-time PCR, RNAi. Market Sectors Expert Frost & Sullivan analysts thoroughly examine the following market sectors in this research:
The following technologies are covered in this research:
High Throughput and Multiplexing Capabilities to Drive Expansion of Gene Expression Solutions in Drug Discovery The revolution in the drug discovery process has been driven by the belief that proteomics will facilitate a better understanding of basic life science processes and thus deliver a high number of drug targets, candidate drugs and novel therapeutics. Advances in understanding cancer biology, human genetics, disease pathogenesis and molecular pharmacology hold great promise for the discovery of new approaches to treat cancers. Progress and expectation have been heightened by initiatives such as the human genome project and technological advances that permit genome-wide analysis of cancer cells and facilitate the synthesis and high throughput screening of selected compounds against defined targets. Some of the major factors driving the expansion of gene expression markets in Europe are the results of high throughput capabilities, increased automation, cost-effectiveness and improved multiplexing capabilities. "Within the realm of drug discovery and development, gene expression helps develop new therapeutics, identify early warning signs of disease and even sub-classify patients based not on symptoms, but on abnormal changes observed in their specific cells," notes the analyst of this research service. "This can lead to the creation of new diagnostic tests and benefit the field of personalised medicine." Although microarrays and other platforms are becoming standard tools for high-throughput analysis of gene expression, nonarray techniques serve to identify and isolate new transcripts to expand knowledge of basic science, as well as create new diagnostics and identify better targets for drug discovery. Techniques that offer multiplexing and enable scientists to screen a large number of genes from a sample simultaneously are becoming increasingly important. Multi-gene patterns of expression can provide a hint of common regulation mechanisms and genes showing similar expression are likely to be related. Cost-effective Pricing Crucial for Market Growth The collection, organisation and analysis of large amounts of biological data, using networks of computers and databases has resulted in data explosion, thereby requiring robust infrastructure to streamline drug discovery processes. Data comparison across platforms is also required, as some laboratories may need to score indigenous microarrays with the equipment and accessories from the commercial sector. Further, to combat issues related to gene expression data validation, data obtained will need to undergo sufficient biological repeat experiments to corroborate findings and secure statistically relevant information. "While microarrays, PCR and RNAi have gained significance in the micro technology era, adding value to the changing paradigm of drug discovery, the major question is whether these technologies are cost effective," remarks the analyst. " Although the potential for drugs to reach faster to the market is apparent, their premium pricing does not justify the use of some of these technologies for routine processes." In this scenario, reliable and consistent date will boost the willingness of the industry to invest. In addition, laboratory automation is likely to promote a faster approach to the preliminary steps, which involve reagent mixing and sample preparation. These processes demand skilled labour and time, thereby indirectly influencing the pricing of gene expression products. Hence, developing the automation process will allow manufacturing processes to become more cost-effective, which will facilitate a reduction in prices. Get Full Details About This Report >> |
|
|||
|
About MarketResearch.com
|
||||